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We investigated whether there is an association between cytomegalovirus (CMV) and Epstein–Barr virus (EBV) IgG levels and risk of
breast cancer before age 40 years. CMV and EBV IgG levels were measured in stored plasma from 208 women with breast cancer
and 169 controls who participated in the Australian Breast Cancer Family Study (ABCFS), a population-based case–control study.
CMV and EBV IgG values were measured in units of optical density (OD). Cases and controls did not differ in seropositivity for CMV
(59 and 57% respectively; P¼0.8) or EBV (97 and 96% respectively; P¼0.7). In seropositive women, mean IgG values were higher in
cases than controls for CMV (1.20 vs 0.98 OD, P¼0.005) but not for EBV (2.65 vs 2.57 OD, P¼0.5). The adjusted odds ratios per
OD unit were 1.46 (95% CI 1.06–2.03) for CMV IgG and 1.11 (0.93–1.33) for EBV IgG. The higher mean CMV IgG levels found in
women with breast cancer could be the result of a more recent infection with CMV, and may mean that late exposure to CMV is a
risk factor for breast cancer.
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It has been hypothesised that some breast cancers might be caused
by late exposure (in adulthood rather than in childhood) to a
common virus (Richardson, 1997). This is consistent with the
geographical distribution of breast cancer. In countries with low
incidence, exposure to common viruses such as cytomegalovirus
(CMV) and Epstein–Barr virus (EBV) occurs early in childhood
and seropositivity is almost invariable before adulthood. In
countries with high incidence, seroconversion typically occurs
later in life and only 60–70% of adults are seropositive.
In contrast to childhood exposure, which is usually asympto-
matic, later exposure to CMV or EBV can cause infectious
mononucleosis, a recognisable illness. A case–control study found
an increased risk of breast cancer with increasing age at onset of
self-reported infectious mononucleosis, and it was suggested that
this might be related to delayed exposure to EBV (Yasui et al,
2001). Infectious mononucleosis is only a surrogate for delayed
CMV or EBV exposure and recall bias may have affected the
results. Therefore, to test the hypothesis above it is important to
determine the CMV and EBV antibody status of women with and
without breast cancer. IgG titres rise initially after infection and
then gradually decline, with residual antibody detectable for
several years (IARC, 1997; Mendez et al, 1999), so IgG levels are
higher in people who have had more recent infections.
We tested stored plasma samples from a population-based
case–control study of early-onset breast cancer, to determine
whether there is an association between IgG antibodies to CMV
and EBV and risk of breast cancer.
MATERIALS AND METHODS
Subjects
The Australian Breast Cancer Family Study (ABCFS) is a
population-based case–control-family study of breast cancer
(Hopper et al, 1994; McCredie et al, 1998; Hopper et al, 1999).
For this study, eligible cases comprised women aged under 40
years with a first diagnosis of invasive breast cancer in 1992–1995
reported to the Victorian or New South Wales Cancer Registries.
Notification of cancer diagnoses is required by legislation in
Victoria and New South Wales. Controls from the electoral rolls
were selected by proportional random sampling based on the
expected age-distribution of the cases, and were aged under 40
years at invitation into the study. Cases and controls were
interviewed in their homes by trained interviewers using the same
questionnaire (addressing known and putative risks for breast
cancer) for cases and controls. Interviews were conducted for 466
cases (72.5% of those eligible) and 408 controls (64.5% of those
eligible). Blood samples were collected from 393 cases and 295
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controls (the protocol during the early part of the study did not
include storing of plasma). Women for whom stored plasma was
available did not differ significantly from those for whom stored
plasma was not available with respect to age or any of the
measured putative risk factors. Approval for the ABCFS was
obtained from the ethics committees of the University of
Melbourne and The Cancer Councils of Victoria and New South
Wales.
Measurement of IgG Antibodies
Measurement of IgG antibodies to CMV and EBV was based on
0.4ml of stored plasma from each woman. Each plasma sample
was tested, blind to case–control status, using standard Victorian
Infectious Diseases Reference Laboratory (VIDRL) enzyme im-
munoassays for CMV IgG and EBV viral capsid antigen IgG with
measurement in units of optical density (OD). Seropositivity was
defined by VIDRL as 40.2 for CMV and X0.2 for EBV.
Statistical analysis
The difference between means was assessed using the t-test and
differences in distribution of IgG values by the Wilcoxon rank-sum
test. The risk of breast cancer was estimated using multivariate
logistic regression with STATA software.
A reference age (age at diagnosis minus 1 year for cases, and age
at interview for controls) was used for all analyses (Hopper et al,
1999). Adjustment for confounding by reference age, verified
history of breast cancer in first-degree relatives, education, country
of birth, state, marital status, BMI, height, age at menarche,
number of live births, and use of oral contraceptives was made as
in previously published case–control analyses (McCredie et al,
1998; Hopper et al, 1999).
RESULTS
Table 1 shows that there was no difference in the prevalence of
seropositivity for CMV or EBV between cases and controls (59 and
57% respectively for CMV, P¼0.8; 97 and 96% respectively for
EBV, P¼0.7). There was no association between risk of breast
cancer and seropositivity after adjusting for potential confounders.
Figure 1A shows that, although the proportion of women who
were seronegative for CMV was similar for cases and controls, the
cumulative distribution of CMV IgG values for seropositive cases
was shifted to the right and had a longer tail than for seropositive
controls. Although there was no significant difference in the
overall distributions (P¼0.1), when restricted to seropositive
women there was evidence that the distributions for cases and
controls differed (P¼0.02). In seropositive women, mean IgG
values were higher in cases than controls for CMV, being 1.20 and
0.98, respectively (P¼0.005). In contrast, Figure 1B shows that the
distribution of EBV IgG values did not differ between cases and
controls (P¼0.7), with the mean EBV IgG values being 2.65 and
2.57, respectively (P¼0.5).
When the effect of IgG values on risk of breast cancer was
examined as a continuous variable, the adjusted odds ratios per
OD unit were 1.46 (95% CI 1.06–2.03) for CMV IgG and 1.11
(0.93–1.33) for EBV IgG (Table 2). Excluding the 18 cases known
to carry a germline mutation in BRCA1 or BRCA2 did not change
these estimates.
DISCUSSION
Our study found evidence of an association between CMV IgG
levels and breast cancer in young women. The higher CMV IgG
levels found in seropositive women with breast cancer could be the
result of a more recent infection with CMV (Mendez et al, 1999),
which would be consistent with the hypothesis that late exposure
to CMV is a risk factor for breast cancer. It is also possible,
however, that an association between breast cancer and CMV
Table 1 Seropositivity for CMV and EBV and risk of breast cancer
Cases (N¼208) Controls (N¼169) Odds ratio
a (95% CI)
CMV positive
b 122 (58.7%) 97 (57.4%) 1.08 (0.68 1.71)
EBV positive
c 201 (96.6%) 162 (95.9%) 1.11 (0.34 3.73)
aAdjusted for reference age, education, country of birth, state, marital status, BMI, height, age at menarche, number of live births, ever use of oral contraceptives, and history of
breast cancer in first-degree relatives.
b40.2 optical density units.
cX0.2 optical density units
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Figure 1 (A) Cumulative distribution of CMV IgG values (OD) for
controls (grey line) and cases (black line). (B) Cumulative distribution of
EBV IgG values (OD) for controls (grey line) and cases (black line).
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agent that has similarities to CMV. Our study did not find evidence
of an association between EBV IgG levels and breast cancer in
young women, although an association between EBV and breast
cancer has been the longer established hypothesis (Bonnet et al,
1999; Magrath and Bhatia, 1999).
Others have investigated the hypothesis that delayed infection is
associated with breast cancer. One study suggested an increased
risk of breast cancer associated with late age at onset of self-
reported infectious mononucleosis (Yasui et al, 2001). The
hypothesis has also been investigated by examining birth cohort
trends in the incidence of breast cancer and Hodgkin’s disease
(Krieger et al, 2003). Several studies have investigated Epstein–
Barr virus gene expression in human breast cancer, with
inconsistent results (Bonnet et al, 1999; Magrath and Bhatia,
1999; Fina et al, 2001; Hermann and Niedobitek, 2003; Xue et al,
2003). Our study is the only one we know of to investigate breast
cancer and EBV or CMV using blood samples and serological
testing.
It is not unreasonable to suggest a viral aetiology for some breast
cancers. Several cancers in humans (cervical cancer, liver cancer,
and Adult T-cell leukaemia) are known to be caused by viruses,
and breast cancer in mice can be caused by a virus; the mouse
mammary tumour virus (MMTV) (Hennighausen, 2000). CMV
could be associated with breast cancer because it is a ubiquitous
virus that is shed in breast milk, as well as in saliva, urine, cervical
secretions, and semen, which implies that CMV persistently infects
epithelial cells (Sissons et al, 2002).
It is possible that chance could explain our findings, even
though the difference between cases and controls for mean CMV
IgG values and the adjusted odds ratio per OD unit for CMV IgG
were both statistically significant. Bias seems an unlikely explana-
tion for our results given the specificity of the association; it is not
obvious to us how bias could cause a spurious association between
breast cancer and CMV but not between breast cancer and EBV,
and antibody testing was carried out by laboratory staff who were
blind to disease status. There is potential for confounding by
unidentified factors, since this is an observational study, however,
adjustment for identified confounding factors made only a small
difference to the odds ratios for CMV IgG and EBV IgG, with the
specificity of association persisting for CMV IgG and breast
cancer.
Not all women with breast cancer in our study had antibodies to
CMV (40% of cases in our study had no antibodies to CMV). This
is compatible with our understanding that during carcinogenesis a
cell must acquire many mutations before it can contribute to
tumorigenesis (Knudson, 1971). CMV infection in adult life may
play a role in some cells acquiring one or more of the genetic
mutations required for the development of breast cancer. An
analysis restricted to women without BRCA1 or BRCA2 mutations
made no difference to the results; however, only 18 women (all
cases) in this study were BRCA1 or BRCA2 carriers.
The main limitation of our study was that it was retrospective,
with blood samples collected after the diagnosis of breast cancer.
Breast cancer or its treatment may cause disruption to the immune
system, leading to increased levels of CMV IgG, but there are no
obvious reasons to expect disruption to the immune system that
would affect CMV IgG levels but not EBV IgG levels. This
specificity of association suggests that the association between
CMV and breast cancer could be causal, but further investigations
are required, such as prospective studies where blood samples
have been taken prior to the diagnosis of breast cancer. Serial
samples would provide more information since the interpretation
of a single high titre of CMV IgG is difficult; normal immune
subjects may have some variation in antibody titre over time, and
the effect of reactivation of latent CMV upon IgG titre is unknown
(Mendez et al, 1999). It would also be important to investigate
whether there is any relationship between CMV and breast cancer
risk in older women, since our study has only focussed on young
women.
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